Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs

Journal of Clinical Investigation

Volumn 105, Issue 4, 2000, Pages 533-539

  Blagosklonny, Mikhail V ^a,b   Robey, Robert ^a   Bates, Susan ^a   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEPSIPEPTIDE; DOXORUBICIN; EPOTHILONE A; EPOTHILONE B; PACLITAXEL; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; VINBLASTINE;

ARTICLE; CANCER CELL DESTRUCTION; CELL KILLING; CELL PROTECTION; CYTOTOXICITY; DNA DAMAGE; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033997563     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI8625     Document Type: Article

References (38)

1. Horwitz, S.B. 1992. Mechanism of action of taxol. Trends Pharmacol. Sci. 13:134-136.
2. Rowinsky, E.K., and Donehower, R.C. 1995. Paclitaxel (Taxol). N. Engl. J. Med. 332:1004-1014.
3. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R.W. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311.
4. El-Deiry, W.S., et al. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
5. Brugarolas, J., et al. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 377:552-557.
6. Deng, C., Zhang, P., Harper, J.W., Elledge, S.J., and Leder, P. 1995. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 82:675-684.
7. Waldman, T., Kinzler, K.W., and Vogelstein, H. 1995. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:5187-5190.
8. Waldman, T., Lengauer, C., Kinzler, K.W., and Vogelstein, B. 1996. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature, 381:643-644.
9. Fearon, E.R., and Vogelstein, B. 1990. A genetic model for colorectal tumorigenesis. Cell. 61:759-767.
10. Vogelstein, B., and Kinzler, K.W. 1992. p53 function and dysfunction. Cell. 70:523-526.
11. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell. 88:323-331.
12. Clarke, A.R., et al. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathway. Nature, 362:849-852.
13. Lowe, S.W., Ruley, H.H., Jacks, T., and Housman, D.E. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:957-967.
14. Bunz, F., et al. 1999. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin Invest. 104:263-269.
15. Lowe, S.W., et al. 1994. p53 status and the efficacy of cancer therapy in vivo. Science. 266:807-810.
16. Lowe, S.W. 1995. Cancer therapy and p53. Curr. Opin. Oncol. 7:547-553.
17. O'Connor, P.M., et al. 1997. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57:4285-4300.
18. Komarov, P.G., et al. 1999. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 285:1733-1737.
19. Bunz, F., et al. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 282:1497-1501.
20. Torres, K., and Horwitz, SB. 1998. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 58:3620-3626.
21. Jordan, M.A., and Wilson, L. 1998. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol. 10:123-130.
22. Blagosklonny, M. V., and Fojo, T. 1999. Molecular effects of paclitaxel: myths and reality. Int. J. Cancer. 83:151-156.
23. Blagosklonny, M.V., Somasundaram, K., Wu, G.S., and El-Deiry, W.S. 1997. Wild-type p53 is not sufficient for serum starvation-induced apoptosis in cancer cells but accelerates apoptosis in sensitive cells. Int. J. Oncol. 11:1165-1170.
24. Agarwal, M.L., Agarwal, A.,Taylor, W.R., and Stark, G.R. 1995. p53 controls both the G2/M and the G1 cell-cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA. 92:8493-8497.
25. Hermeking, H., et al. 1997. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol. Cell. 1:3-11.
26. Wang, X.W., et al 1999. GADD45 induction of a G2/M cell cycle checkpoint. Proc. Natl. Acad. Sci. USA 96:3706-3711.
27. Blagosklonny, M.V., Iglesias, A., Zhan, Z., and Fojo, T. 1998. Like p53, the proliferation-associated protein p120 accumulates in human cancer cells following exposure to anticancer drugs. Biochem. Biophys. Res. Commun. 244:368-373.
28. Ueda, H., et al. 1994. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. Anti-tumor activities on experimental tumors in mice. J. Antibiot. (Tokyo). 47:315-323.
29. Nakajima, H., Kim, Y.B., Terano, H., Yoshida, M., and Horinouchi, S. 1998. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 241:126-133.
30. Fisher, D.E. 1994. Apoptosis in cancer therapy: crossing the threshold. Cell. 78:539-542.
31. Kastan, M.B., Canman, C.E., and Leonard, C.J. 1995. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. 14:3-15.
32. Kaelin, W.G.J. 1999. Choosing anticancer drug targets in the postgenomic era. J. Clin. Invest. 104:1503-1506.
33. Shapiro, G.I., and Harper, J.W. 1999. Anticancer drug targets: cell cycle and checkpoint control. J. Clin. Invest. 104:1645-1653.
34. Sellers, W.R., and Fisher, D.H. 1999. Apoptosis and cancer drug targeting. J. Clin. Invest. 104:1655-1661.
35. Yu. D.H., et al. 1998. Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21(Cip), which inhibits p34(Cdc2) kinase. Mol. Cell. 2:581-591.
36. Barboule, N., Chadebech, P., Baldin, V., Vidal, S., and Valette, A. 1997. Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell lines. Oncogene. 15:2867-2875.
37. Li, W., Fan, J., Banerjee, D., and Bertino, J.R. 1999. Overexpression of p21 (waf1) decreases G2-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein. Mol. Pharmacol. 55:1088-1093.
38. Stewart, Z.A., Mays, D., and Pietenpol, J.A. 1999. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Res. 59:3831-3837.